Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Pandemic Burden in Severe Mental Disease Patients (PsyCOVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04357769
Recruitment Status : Recruiting
First Posted : April 22, 2020
Last Update Posted : April 22, 2020
Sponsor:
Information provided by (Responsible Party):
Felice Iasevoli, Federico II University

Brief Summary:

Despite being originated in Wuhan, in the China mainland region of the Hubei, Italy has been the hardest-hit country in the world by the COVID-19 pandemic during the month of March.

Due to the uncontrollable spread of the contagion, the Italian Government has been forced to impose a series of restrictions and social distancing measures, culminating in the extension of lockdown to the entire Italian territory on March 8th.

During this period, the general population has been overwhelmed by feelings of worry, anxiety, and discomfort. The discomfort is reinforced by the lengthening of the lockdown, to the point that it may be considered as a mass model of chronic or subchronic mild stress.

The predictable effects of this stress on mental health have already been claimed, Post-traumatic symptoms were found in 7% among 285 Wuhan and surrounding cities' residents during the COVID-19 outbreak. A recent survey in the Italian general population reported similar outcomes.

In this context, the psychic conditions of the most fragile ones, i.e. those already affected by a severe mental disorder, represent a major concern. Having a history of psychiatric illness is regarded as one of the most relevant predictors of a negative psychological impact of quarantine. Patients with severe mental disorders may be among the hardest hit subjects, as they may be more vulnerable by the COVID-19 outbreak for a series of clinical and psychological factors. In the Italian context, the vulnerability of these patients may be increased by the lockdown of mental health services as a consequence of mass quarantine and optimization of health resources toward action to contrast COVID-19-related sanitary emergencies.

Despite several reports investigated the psychological effects of COVID-19 pandemic on health-care workers, COVID-19 affected people, or the general population, at the moment, no study has investigated the effects of the distress caused by fear of contagion and mass quarantine on severe mental disorder patients. The present study aimed at providing a first evaluation of anxiety, depressive, stress-related symptoms in these patients.


Condition or disease Intervention/treatment
Psychological Distress COVID Severe Mental Disorder Other: PSS (Perceived Stress Scale) Other: GAD-7 (7-item Generalized Anxiety Disorder) Other: PHQ-9 (9-item Patient Health Questionnaire) Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales Other: Zaritt Burden Interview

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: A Study of Perceived Distress and Psychological Burden in Patients Suffering From Severe Mental Diseases During the COVID-19 Pandemic in Italy
Actual Study Start Date : April 10, 2020
Estimated Primary Completion Date : April 20, 2020
Estimated Study Completion Date : April 25, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Patients
Individuals aged 18-70 years with a diagnosis of severe mental disorder (schizophrenia or psychosis spectrum disorder; bipolar disorder; major depressive disorder) who were in a condition of psychopathological compensation, had their last clinical evaluation at the University of Naples Federico II outpatient unit of Psychiatry during January-February 2020, were not positive or suspected positive for COVID-19, and were under strict quarantine
Other: PSS (Perceived Stress Scale)
Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Other: GAD-7 (7-item Generalized Anxiety Disorder)
Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Other: PHQ-9 (9-item Patient Health Questionnaire)
Self-administered scale for the evaluation of depressive symptoms in the last weeks

Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

Controls (General Population)
Individuals aged 18-70 years who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine (e.g. not getting out for work)
Other: PSS (Perceived Stress Scale)
Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Other: GAD-7 (7-item Generalized Anxiety Disorder)
Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Other: PHQ-9 (9-item Patient Health Questionnaire)
Self-administered scale for the evaluation of depressive symptoms in the last weeks

Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

First-degree Relatives
Individuals aged 18-70 years who were first-degree relatives and caregivers of an individual included in the Patients group, who had not a psychiatric condition nor were positive or suspected positive for COVID-19 and were under strict quarantine
Other: PSS (Perceived Stress Scale)
Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Other: GAD-7 (7-item Generalized Anxiety Disorder)
Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Other: PHQ-9 (9-item Patient Health Questionnaire)
Self-administered scale for the evaluation of depressive symptoms in the last weeks

Other: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

Other: Zaritt Burden Interview
Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden




Primary Outcome Measures :
  1. Perceived Stress Scale (PSS) outcome [ Time Frame: 10 days ]
    Significant differences among groups in the mean Perceived Stress Scale (PSS) score, which measures the stress severity perceived by the subjects in the last month. The scale is constituted by 10 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 40. Higher total scores indicate a worse outcome


Secondary Outcome Measures :
  1. Generalized Anxiety Disorder (GAD-7) scale outcome [ Time Frame: 10 days ]
    Significant differences among groups in the mean Generalized Anxiety Disorder (GAD-7) scale score, which measures anxiety symptoms' severity in the last two weeks. The scale is constituted by 7 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome

  2. Patient Health Questionnaire (PHQ-9) scale outcome [ Time Frame: 10 days ]
    Significant differences among groups in the mean Patient Health Questionnaire (PHQ-9) scale score, which measures depressive symptoms' severity in the last two weeks. The scale is constituted by 9 items that are self-rated by the subject on a 0-3 Likert scale. The scale minimum total score is 0, the maximum is 21. Higher total scores indicate a worse outcome

  3. Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome [ Time Frame: 10 days ]
    Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale score. The SPEQ scale is designed for the assessment of current sub-threshold psychotic symptoms in multiple domains. The Paranoia subscale measures persecutory/reference ideas and is constituted by 15 items that are self-rated by the subject on a 0-5 Likert scale. The subscale minimum total score is 0, the maximum is 75. Higher total scores indicate a worse outcome

  4. Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome [ Time Frame: 10 days ]
    Significant differences among groups in the mean Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale score. The Grandiosity subscale measures grandiosity/megalomaniac ideas and is constituted by 8 items that are self-rated by the subject on a 0-3 Likert scale. The subscale minimum total score is 0, the maximum is 24. Higher total scores indicate a worse outcome

  5. Caregiver Burden [ Time Frame: 10 days ]
    Significant correlations between mean Zarit Burden Interview (ZBI) and mean scores on the Perceived Stress Scale (PSS). The ZBI is designed for the assessment of caregiver burden. The scale is constituted by 22 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 88. Higher total scores indicate a worse outcome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
All subjects included in the study should have been under mass quarantine in the last month and should have been exposed to similar distressing factors during the SARS-CoV-2 outbreak in Italy
Criteria

Inclusion Criteria:

  • DSM-5 Diagnosis of Schizophrenia or Psychosis Spectrum; Bipolar Disorder; REcurrent Major Depressive Disorder
  • Linguistic and cognitive ability to complete the rating scales
  • Written informed consent
  • Psychopathological compensation at last clinical evaluation on January-February 2020

Exclusion Criteria:

  • SARS-CoV-2 positive, suspected positive, or in recent close contact with positive ones
  • Not under strict quarantine, due to work reasons or to any other reason allowing to overcome quarantine
  • Current or recent hospitalization (i.e. on March-April), for any reason
  • Intellectual disability
  • Psychiatric disturbances secondary to general medical conditions or substances
  • Serious medical conditions with infaust prognosis or severely affecting the quality of life
  • Living in Northern Italy

Adjunctive Exclusion Criteria for the General Population and Caregivers:

  • Psychiatric Disorder, of any type

Adjunctive Exclusion Criteria for the General Population:

  • First degree relative or caregiver of a psychiatric patient

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04357769


Locations
Layout table for location information
Italy
University of Naples "Federico II" Recruiting
Napoli, Italy, 80131
Contact: Felice Iasevoli, M.D., Ph.D.    +390817462647    felice.iasevoli@unina.it   
Sponsors and Collaborators
Federico II University
Layout table for additonal information
Responsible Party: Felice Iasevoli, Associate Professor of Psychiatry, Federico II University
ClinicalTrials.gov Identifier: NCT04357769    
Other Study ID Numbers: 152/20
First Posted: April 22, 2020    Key Record Dates
Last Update Posted: April 22, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mental Disorders